Skip to main content

Advertisement

Figure 1 | Breast Cancer Research

Figure 1

From: Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

Figure 1

Patient distribution according to molecular characteristics and St Gallen 2011 and 2013 intrinsic molecular subtype definitions. The threshold of ≥14% for Ki-67 in the 2011 definition was derived from comparison with gene array data as a prognostic factor [3, 4], whereas the threshold of ≥20% in the 2013 definition was approved by the majority of the expert consensus panel [1]. HER2, Human epidermal growth factor receptor 2; PgR, Progesterone receptor.

Back to article page